By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:







CEO: Ian T. Clark

CEO: Ed Harrington

Chief Medical Officer: Sandra J. Horning, MD

Chief Compliance Officer: Frederick C. Kentz, III


Please click here for clinical trial information.

Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer 10/19/2016 6:14:07 AM
FDA Approves Genentech (RHHBY)'s Lucentis Pre-Filled Ranibizumab Syringe 10/14/2016 12:20:25 PM
Charles River  (CRL) Announces Extension Of Integrated Discovery Program With Genentech (RHHBY) 10/11/2016 8:46:32 AM
FDA Bestows Priority Review to Genentech (RHHBY)’s Lucentis sBLA for mCNV 10/11/2016 6:38:08 AM
Genentech (RHHBY) Scores Another Win as Tecentriq Succeeds in Late-Stage Lung Cancer Trial 10/10/2016 6:05:08 AM
Exelixis (EXEL) Announces Genentech (RHHBY) Presentation Of Preliminary Phase 1b Results For The Combination Of Cobimetinib, Vemurafenib And Atezolizumab At ESMO 2016 Congress 10/7/2016 8:54:50 AM
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Actemra (Tocilizumab) In Giant Cell Arteritis, A Form Of Vasculitis 10/5/2016 10:31:41 AM
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status 10/4/2016 6:31:59 AM
Next in a String of Deals, Korea’s Hanmi Pharma (128940.KS) Inks $910M Deal with Genentech (RHHBY) 9/29/2016 5:29:33 AM
Genentech (RHHBY) Gambles $310 Million+ on German Biotech BioNTech's mRNA Cancer Vaccine Tech 9/21/2016 5:46:34 AM